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Response Letter. 
Re: Reviewer response for manuscript  
Klaus A. Miczek PhD 
Principal Editor of Psychopharmacology 
 
Dear Dr. Miczek -- 
 
Sincere thanks to you and the reviewing team for considering our manuscript for publication in 
Psychopharmacology. We have addressed each comment, and an itemized reply can be found 
below this passage. The reviewer comment will be boldfaced, and our reply will follow. 
 
We are happy to make additional edits to the manuscript as you and the reviewing team see fit. 
 
Sincerely, 
Chicora Oliver. 
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Comments;Response Letter.docx
Editorial Comment 
 
We have now included a Table that specifies effects of synthetic cathinones administered with 
(or following) other illicit drugs including cocaine and methamphetamine. We believe this Table 
is a valuable reference that will refer readers to original research reports addressing this critical 
issue. We regretfully were unable to construct a timeline of historical development of synthetic 
cathinones but hope the reviewing team finds the written text to be sufficient. 
 
Reviewer 1 
 
(1-2) “The review comes to a little bit of an abrupt end… (add) recommendation for 
professional education (ED personnel)...”. We thank Reviewer 1 for this comment and have 
expanded our concluding passages. Specifically, we reiterate take-home messages that drugs 
marketed as something other than synthetic cathinones may, indeed, contain one or more 
synthetic cathinone agents. We expand on potential factors contributing to suicides associated 
with synthetic cathinone use. 
 
All minor corrections were performed in the revised manuscript. 
 
Reviewer 2 
 
(1-2) “In the abstract…identify "ecstasy" by its chemical name.” and “Page 9, line 10 - 
please define "ersatz".” We thank Reviewer 2 for noting these issues with clarity. We define 
ecstasy in the abstract and use the clearer term “counterfeit” in place of “ersatz”.  
 
(3) “Toxicological Assessment subsection - it should be mentioned that references 
standards for many parent compounds are now available (i.e., Cayman Chemical, 
Cerillian). Also, in this section it should be mentioned that GC-MS methods are also used 
for detection and analysis.” These important changes were made to the revised text. Discussion 
of toxicological assessment now cites the availability of reference standards as well as GC-MS 
testing methods. 
 
(4) “ It would be helpful to know, if such information is available, the degree to which 
some drugs such as MDMA are adulterated with cathinones. For example, in seized 
MDMA tablets, what percent of the tablets are MDMA vs. cathinones? Likely there are 
trace amounts, but the relative contamination levels could be useful to discuss briefly.” We 
agree with Reviewer 2 that having this information would be incredibly useful. However, such 
data is not currently available. The coauthors have personally contacted likely sources of this 
information (e.g. NFLIS) but have been unable to find data relevant to this issue.  
 
(5) “Consequences subsection - when discussing the ability of cathinones to increase, 
DA, NE, 5-HT, the authors should briefly clarify that these increases are in extracellular 
levels, not tissue content, and are achieved by presynaptic transporter blockade or via 
acting as transporter substrates. The phrase "increase dopamine, norepinephrine, and 
serotonin..." is too general.” This important oversight is corrected in the revised text. We made 
clear that neurotransmitters modulated by synthetic cathinones are done so in the synapse and 
result from both transporter blocking and substrate properties of these drugs.  
 
(6) “The final Conclusions section is very short and could be expanded with a 
discussion of some critical issues. These could include, but are not limited to, the issue of 
constant development of new cathinone derivatives, identification of synthetic cathinone 
metabolites which might have long elimination half lives which better aid in detection in 
biological samples as markers of prior use, identification of unique behavioral or 
physiological biomarkers of contaminated drug use, etc.” We thank Reviewer 2 for this 
incredibly helpful feedback. The Conclusion (now “Concluding Remarks”) was expanded to 
discuss the potential for death from overdose or fatal self-harm and how there is a need for more 
awareness of the symptoms of synthetic cathinone overdose. We also discuss the need for more 
research on the behavioral and neurotoxic effects of synthetic cathinone drug combinations. We 
also highlight the need for studies that examine how environmental factors such as temperature 
alter the effects of synthetic cathinones use. Finally, we close by stating that these efforts may 
aide in the development of interventions that address the unique problem of synthetic cathinone 
adulteration of illegal drugs. We believe these changes greatly strengthen the text and hope the 
reviewing team find these changes to be sufficient. 
 
 
 
 
Synthetic Cathinone Adulteration of Illegal Drugs 
Chicora F. Oliver*1, Joseph J. Palamar2, Alberto Salomone3, Steven J. Simmons1, 5, Helene 
Philogene-Khalid4, Nick Stokes-McCloskey1, Scott M. Rawls1 
 
1Center for Substance Abuse Research,  Lewis Katz School of Medicine at Temple University, 
3500 North Broad Street, 882A, Philadelphia, PA 19140, USA.  
 
2Department of Population Health, 227 E. 30th Street, 7th Floor, New York, NY 10016, USA.  
 
3Centro Regionale Antidoping “A. Bertinaria”, Regione Gonzole 10/1, 10043 Orbassano, Torino, 
Italy.  
 
4Department of Psychiatry, 3400 Spruce Street, Philadelphia, PA 19104.  
 
5Department of Anesthesiology and Critical Care Medicine, Children’s Hospital of Philadelphia 
Research Institute, Philadelphia, PA, 19104. 
 
 
 
 
 
 
 
Conflicts of Interest: There are no conflicts of interest to report. 
Acknowledgement of funding: National Institutes of Health, National Institute on Drug Abuse 
R01 DA039139 to SMR. SJS was supported by institutional training fellowships (T32 
DA007237 to Ellen M. Unterwald, T32 NS007413 to Michael B. Robinson). 
 
*Corresponding Author 
Chicora F. Oliver 
Center for Substance Abuse Research 
Lewis Katz School of Medicine at Temple University 
Email: chicoraoliver@temple.edu  
Phone: 215-707-3656 
Fax: 215-707-6932 
Author’s Response to Reviewers‘ Comments Click here to access/download;Manuscript;Manuscript
RESUBMISSION.docx
Click here to view linked References
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
Abstract. 
Rationale. Current prevalence estimates of synthetic cathinone (“bath salts”) use may be 
underestimates given that traditional metrics (e.g., surveys, urinalysis) often fail to capture the 
emergent issue of synthetic cathinone adulteration of more common illegal drugs such as ecstasy 
(3,4-methylenedioxymethamphetamine). 
Objectives. This review examines the evolution of synthetic cathinones and prevalence of use 
over the past decade in the United States. We also review methods of self-report and biological 
testing of these compounds as well as adverse outcomes associated with adulterated drug use. 
Results. Synthetic cathinone use emerged in the United States by 2009 with use associated with 
tens of thousands of poisonings. Reported poisonings and self-reported use have substantially 
decreased over the past five years. However, our review suggests that current estimates of use 
are underestimates due to underreporting stemming primarily from unknown or unintentional use 
of adulterated formulations of relatively popular illegal drugs, such as ecstasy.  
Conclusions. While intentional synthetic cathinone use has decreased in recent years, evidence 
suggests prevalence of use is underestimated. Testing of drugs and/or biological specimens can 
improve the accuracy of synthetic cathinone use estimates. Furthermore, we advocate that 
researchers and clinicians should become better aware that exposure to these potent compounds 
(e.g., as adulterants) often occurs unknowingly or unintentionally. To improve our understanding 
of synthetic cathinone adulteration, research utilizing a combinatorial approach (survey and 
biological testing) will help more accurately determine the prevalence and impact of this public 
health issue. 
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Keywords. 
Synthetic cathinones; novel psychoactive substances; ecstasy; adulteration; addiction. 
  
Abbreviations. 
α-PVP - α-pyrrolidinopentiophenone 
4-MMC - 4-methylmethcathinone 
5-HT - serotonin 
AAPCC - American Association of Poison Control Center 
DA - dopamine 
DEA - Drug Enforcement Administration 
ED – emergency department 
EDM - electronic dance music 
MDMA - 3,4-methylenedioxymethamphetamine 
MDMC - 3,4-methylenedioxymethcathinone 
MDPV – 3,4-methylenedioxypyrovalerone 
NA - noradrenaline 
NFLIS - The National Forensic Laboratory Information System 
NPS – new psychoactive substance 
PCP – phencyclidine 
UHPLC-HRMS - ultra high performance-tandem mass spectrometry-high resolution mass 
spectrometry 
UHPLC-MS/MS - ultra high performance liquid chromatography-tandem mass spectrometry 
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Synthetic Cathinone Adulteration of Illegal Drugs. 
A growing number of studies have demonstrated synthetic cathinone adulteration of 
illegal drugs such as ecstasy or 3,4-methylenedioxymethamphetamine (MDMA, “ecstasy”) (Rust 
et al. 2012; Palamar et al. 2016d, 2017b; Salomone et al. 2017). Various synthetic cathinones 
(colloquially, “bath salts”) produce effects similar to those of MDMA, and therefore adulteration 
or replacement of ecstasy with synthetic cathinones may go unnoticed by some users. However, 
synthetic cathinones can be much more potent than the drugs they are intended to mimic 
(Baumann et al. 2012), and thus the risk of overdose and death can be greatly increased. While 
growing awareness, legal restrictions, and sensational media reporting seem to have reduced 
intentional synthetic cathinone use, synthetic cathinones continue to be detected in users unaware 
of consumption. For example, two recent studies analyzing hair samples of ecstasy-using 
electronic dance music (EDM) party attendees found that 50-68% of those testing positive for 
synthetic cathinones denied known use (Palamar et al. 2016c, 2017c). Retrospective analysis of 
the hair of drug users confirms the presence of synthetic cathinones in those who report MDMA 
and/or other drug use but deny conscious consumption of synthetic cathinones (Rust et al. 2012; 
Palamar et al. 2016c, 2017c). These and other studies reviewed in this manuscript indicate that 
current prevalence estimates of synthetic cathinone use (e.g., in the United States) are likely 
underestimates, and we believe addressing these potential underestimates is critical for 
improving public health and safety. 
Evolution of Synthetic Cathinone Use. 
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Synthetic cathinones are psychoactive substances manufactured to mimic the stimulating 
effects of naturally occurring, plant-based cathinones. The psychoactive properties of cathinones 
have been appreciated for several millennia through the practice of chewing leaves of the 
cultivated perennial shrub khat, C. edulis (native to East Africa/Arabian Peninsula). Subjective 
effects of khat leaf chewing include allayed fatigue and elated mood (Alles et al. 1961; Numan 
2004). In the mid-20th century, means of expedited international trade allowed perishable khat to 
be exported to the United States, United Kingdom and elsewhere. The United Nations Narcotics 
Laboratory successfully isolated (±)-cathinone as the principal psychoactive agent from khat 
leaves in the early 1970s (for discussion, see Kalix 1984) and noted structural similarity to 
phenylisopropylamine (amphetamine) with the addition of a ketone at cathinone’s β-carbon 
atom. In 1987, Glennon and colleagues (1987) discovered alarming potency in the amphetamine-
like subjective effects of methcathinone among animals, although readers should note the 
original synthesis of methcathinone was performed in the 1920s in an effort to produce ephedrine 
homologs (Hyde et al. 1928). In 1994, the Drug Enforcement Agency (DEA) of the United States 
designated methcathinone as a Schedule I illegal drug (State Department 1994), and use of 
synthesized cathinones remained low for the subsequent two decades. 
Cathinone-derived psychostimulant drugs surged in popularity in the late 2000s most 
notably across the United Kingdom and United States. Novel modifications of the parent 
compound yielded abuse-prone agents including amphetamine-like 4-methylmethcathinone (4-
MMC, “mephedrone”) and 3,4-methylenedioxypyrovalerone (MDPV), as well as the 
empathogenic agent 3,4-methylenedioxymethcathinone (MDMC, “methylone”), which 
structurally resembles MDMA. The surge in use is attributed to marketing on the “dark web” as 
novel formulations obviated legal persecution for several years by classifying agents as “not for 
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human consumption” with product names including “blue silk,” “vanilla sky,” and “white 
lightning” (European Monitoring Centre for Drugs and Drug Addiction 2015; Drug Enforcement 
Agency 2017). The National Forensic Laboratory Information System (NFLIS) reported 34 
analytically-confirmed cases of synthetic cathinone seizures across 8 states in 2009. In 2010, 
NFLIS reported 628 cases across 27 states (NFLIS 2011), and by July 2012, mephedrone and 
MDPV had become classified as Schedule I by the DEA under emergency order. Consequently, 
NFLIS reported methylone as the most prevalent synthetic cathinone in 2013 (12,067 cases, 
71.8% of all synthetic cathinone cases; NFLIS 2015). 
“Second generation” synthetic cathinones surfaced after methylone was scheduled in 
April 2013 and included 3,4-methylenedioxy-N-ethylcathinone (ethylone) and α-
pyrrolidinopentiophenone (α-PVP). Synthetic cathinones seized in this “second generation” era 
possessed ethyl, butyl, pyrrolidinyl, fluoro and benzyl substitutions against cathinone’s backbone 
(for review, see Majchrzak et al. 2018). Use of the aforementioned synthetic cathinones is 
associated with health risks ranging from injection site irritation/infection to 
paranoia/hallucinatory delirium, sympathomimetic toxicity, serotonin syndrome, and sudden 
cardiac death (Wood et al. 2010; Dorairaj et al. 2012; Carbone et al. 2013). α-PVP, commonly 
referred to as “flakka,” was linked to 63 deaths in Fort Lauderdale, Florida within a 16-month 
period (CBS 2016), and the bizarre behavior linked with its use has earned it the street name 
“zombie drug” (Nóbrega and Dinis-Oliveira 2018). Data as of mid-2017 show β-keto-
ethylbenzodioxolylpentanamine (N-ethylpentylone, “ephylone”), which appears to possess 
appreciably greater potency than MDMA, is the most widely used synthetic cathinone in the 
United States, with over 2,500 cases reported (DEA 2017; Krotulski et al. 2018). Furthermore, 
13 individuals were hospitalized in New Zealand from mistakenly consuming high doses of 
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ephylone in March 2018 (Newshubb 2018). These recent data confirm that novel synthetic 
cathinones (administered alone or in formulation) continue to be produced and thus pose a threat 
to public health on an international scale. And while deliberate abuse of synthetic cathinones has 
ostensibly declined, the variability of drug adulteration obscures the public’s real rates of 
consumption. 
Epidemiology of Synthetic Cathinone Use. 
The American Association of Poison Control Center’s (AAPCC) National Poison Data 
System tracks reported poisonings throughout the United States. AAPCC did not begin receiving 
reports of exposure to synthetic cathinones until 2009 - this first year, AAPCC received 298 
cases of synthetic cathinone poisonings (Wood 2013). In 2011, reports of exposures increased to 
>6,000 (Wood 2013), and synthetic cathinones were involved in over 20,000 drug-related 
emergency department (ED) visits (Substance Abuse and Mental Health Services Administration 
2011). Between 2011 and 2013, there were nearly 10,000 reported exposures to synthetic 
cathinones; however, exposures decreased to fewer than 1,000 between 2014 and mid-2015 
(Wood 2013; AAPCC, 2016). Recent public data are not available on hospitalizations or 
poisonings involving synthetic cathinones in the United States for recent years, but there is 
evidence to suggest diminution. While national drug-related ED data after 2011 are not available, 
it should be noted that in light of the prevalence of ecstasy use decreasing dramatically after the 
early 2000s (Johnston et al. 2018), ED visits related to “ecstasy” use increased several-fold from 
4,452 in 2001 to 22,498 in 2011 (Substance Abuse and Mental Health Services Administration 
2011). The steep increase in “ecstasy”-related ED visits through 2011 coincided with popularity 
of use of the drug in powder form (referred to as “Molly”), which may increase likelihood of 
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adulteration (Palamar 2017). It is unknown to what extent synthetic cathinones were 
unknowingly ingested by users as toxicology testing was not utilized in EDs. 
     Monitoring the Future (MTF), an annual nationally representative survey of high school 
seniors (12th graders), is the only national survey in the US to query “bath salts” (synthetic 
cathinone) use. MTF first asked about “bath salts” in 2012, and 1.3% of students reported past-
year use (Johnston et al. 2018). Prevalence of past-year use appears to have decreased with 0.6% 
reporting use in 2017 (Palamar 2015; Johnston et al. 2018). However, a major limitation of the 
MTF survey is that “bath salts” are not clearly defined, nor are examples of specific compounds 
provided. Few studies have examined synthetic cathinone use in greater depth. In 2016, a study 
of EDM party attendees tested survey methods querying synthetic cathinone use and found that 
nearly a tenth (9.3%) of those denying overall use of synthetic cathinones then reported use of a 
specific synthetic cathinone on the following page (Palamar et al. 2017a), reflecting widespread 
confusion as to what drugs constitute “bath salts.” This was most commonly the case with 
methylone and mephedrone, which are synthetic cathinones with empathomimetic, ecstasy-like 
effects. Further, an analysis of type-in responses in the National Survey of Drug Use and Health 
found that type-in responses of other drugs used led to a severe underestimate of only 0.05% of 
individuals in the United States ever using synthetic cathinones or other novel phenethylamines 
or euphorigenic stimulants (Palamar et al. 2015b). These findings reveal that more commonly 
employed means of assessing drug use (e.g., surveys) may underestimate synthetic cathinone 
use, in part, due to lack of drug education among users. Few other studies have queried synthetic 
cathinone use on surveys. One survey of college students in 2011-2012 included a question about 
use of synthetic cathinones and a specific compound (MDPV), and use was reported by only 1% 
of the sample (Miller and Stogner 2014). Similarly, a survey of attendees of gay clubs, hip hop 
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clubs, indie rock clubs, and EDM clubs in New York City (NYC) in 2012 asked about use of 
synthetic cathinones or mephedrone, and similarly, only 1% reported use (Kelly et al. 2013). 
Surveys focusing on EDM party attendees, however, have tended to find higher 
prevalence of reported synthetic cathinone use. We believe higher prevalence is detected in this 
population for four reasons. First, EDM party attendees are at high risk for using various drugs 
(Ross et al. 2003; Palamar et al. 2015a, 2017b; Kurtz et al. 2017), and use of other drugs has 
been found to be a major risk factor for synthetic cathinone abuse (Palamar et al. 2015b, 2017b; 
Fernández-Calderón et al. 2018). Second, various synthetic cathinone compounds have similar 
effects to common club drugs such as ecstasy, with some compounds like mephedrone 
functioning as counterfeit replacements (Brunt et al. 2011a). Third, surveys of EDM party 
attendees tend to ask about multiple synthetic cathinone compounds and not just synthetic 
cathinones as an overall category, and it appears that asking about multiple compounds increases 
the likelihood of recognizing a specific compound that was used. Finally, EDM party attendees 
have been found to be at high risk for unknowingly or unintentionally using synthetic cathinones 
as these compounds are common adulterants in drugs such as ecstasy (Palamar et al. 2016c, 
2017c). 
A self-selected online sample of past-year drug-using nightclub attendees who 
participated in the Global Drug Survey in 2013 found that one-out-of-ten (10%) reported ever 
using at least one synthetic cathinone queried (Palamar et al. 2016b). Most (8%) reported 
methylone use, 5% reported mephedrone use, and 2% reported MDPV use. More recently, time-
space sampling and weighting methods have been used by some studies to yield more accurate 
estimates of synthetic cathinone use from venue-based recruitment in the EDM scene. A study of 
young adult (age 18-25) EDM party attendees in 2015 estimated that 7% of attendees had used at 
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least one (of 26) synthetic cathinone compound, with methylone (3%) being the most prevalent 
(Palamar et al. 2016a). In 2016, similar lifetime prevalence of 7.7% was estimated among EDM 
attendees in NYC age 18-40 (Palamar et al. 2018); however, in a new 2017 cohort of attendees, 
estrimated prevalence of known use decreased in half to 3.5% (Palamar 2018). 
         Prevalence estimates of synthetic cathinone use also tend to be underestimates because 
many users of drugs such as ecstasy consume these compounds unknowingly, as synthetic 
cathinones are common adulterants or replacements (discussed in detail below). In fact, during a 
recent survey of EDM party attendees in NYC, 30% of respondents agreed that “bath salts” are 
sometimes found in Molly, and 15% reported believing they might have unknowingly used “bath 
salts” (Palamar 2018). This suggests many EDM attendees are aware of the high potential for 
adulteration, hence extensive interest in “drug checking” in which an individual’s drug is tested 
for purity (Barratt et al. 2018). To our knowledge, no studies have examined prevalence of 
adulteration in the United States, and this is likely due to high legal risk for both users and drug 
checkers. However, studies have begun to analyze biological specimens of users to determine 
whether they have used synthetic cathinones. 
Toxicological Assessment of Synthetic Cathinone Use. 
After the presence of synthetic cathinones on the black market became recognized, 
forensic and clinical laboratories worldwide had to face the analytical challenge of identifying 
and quantifying these new drugs in various biological matrices. The commercial unavailability of 
reference standards for the parent drugs and their metabolites, the lack of updated and 
comprehensive immunoassays for their detection, and the insufficient investigation of their 
metabolic transformation after intake represented just the main problems toward the 
identification and quantification of synthetic cathinones (Salomone et al. 2017). At the moment, 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
most of the aforementioned challenges have been at least partially overcome. For example, 
reference standards for many parent compounds are now available from companies such as 
Cayman Chemical and Cerillian. Gas chromatography with mass spectrometry (GC-MS) is also 
employed to assess synthetic cathinone use (Alvarez et al. 2017). The most recent equipment 
based on ultra high performance-tandem mass spectrometry (UHPLC-MS/MS) and high 
resolution mass spectrometry (UHPLC-HRMS) allows the detection of expansive synthetic 
cathinone panels within a single analytical run. Several laboratories currently embrace this 
promising advent by offering screening and confirmation analysis for synthetic cathinones (Zuba 
and Adamowicz 2018; Marchei et al. 2018). 
         Much is yet to be discovered about the current diffusion of synthetic cathinones among 
the general population and in high-risk populations. Synthetic cathinones are eliminated from the 
urine, blood, and saliva of users within hours or days, which limits the ability of toxicological 
confirmation. This is especially concerning in cases of hospitalization and death resulting from 
intentional or unintentional use of synthetic cathinones (Salomone et al. 2017). As a 
consequence, a number of unresolved issues are raised, including the number and variety of 
synthetic cathinones present in different countries, their frequency of use, and user 
demographics. To circumvent the limitations of conventional biological samples (e.g., blood, 
urine, saliva), the detection of synthetic cathinones in alternative matrices (i.e., hair samples) was 
proposed as a practical means to provide preliminary information on the black market 
penetration of synthetic cathinones (Rust et al. 2012; Salomone et al. 2016b) in specific 
territories and populations. The keratin matrix incorporates parent synthetic cathinones 
consumed over extended time periods, providing access to a much wider diagnostic window than 
blood and urine. This feature, combined with the analytical performance of the latest generation 
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of UHPLC-MS/MS instruments, allows researchers to obtain significant information about past 
use ‒ even a single intake of any targeted compound, with older periods of use corresponding to 
the hair segments more distant from the hair root (Salomone et al. 2016b). In particular, 
analytical methods must guarantee high sensitivity: due to their high pharmacological potency in 
vitro, it is likely that synthetic cathinones are active in relatively low doses (and therefore are 
consumed in low doses, and present at lower levels in hair). 
         Remarkably, the majority of the published studies describing novel synthetic drug 
detection in hair samples reported the frequent occurrence of polydrug use (Kintz et al. 2015; 
Salomone et al. 2016a). One explanation for this is because the consumers are unaware of the 
actual composition of the products. Today, despite the general knowledge that no systematic 
correspondence exists between the trade or the street name and real content of the 
pill/powder/crystal/herbal blend, consumers hardly ever have means of verifying what they 
purchased. This is not surprising as synthetic cathinones are semi-clandestine preparations in 
which the active ingredients may vary over time. This inconsistency in the content of illegal 
drugs implies that consumers do not have control of the potency and efficacy of the products to 
be consumed. Even when synthetic cathinones are purchased online or used intentionally, 
substantial risk exists that they are mislabeled either because they contain chemical analogs of 
the ordered drug (e.g., pentedrone instead of 3,4-dimethylcathinone) or because the active agent 
differs from what was advertised by the dealer or via the website (Brunt et al. 2017). In this 
scenario, hair testing offers a unique perspective in the investigation of drug consumption, 
provided a large panel of target analytes. The extended diagnostic time window covered by the 
keratin matrix (unlike urine, blood, and saliva) allows retrospective investigation of drug 
prevalence and diffusion of any targeted psychoactive substance. In particular, the occurrence of 
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poly-use and unintentional intake of synthetic cathinones can be revealed by means of hair 
analysis, possibly combined with surveys. 
Synthetic Cathinone Adulteration of Illegal Drugs. 
         Rust et al. (2012) examined hair samples from 2009 to 2010 from individuals who 
originally tested positive for amphetamines and/or MDMA (n=325) (Rust et al. 2012). Hair was 
collected as part of a driving ability assessment and employed liquid chromatography with 
tandem mass spectrometry (LC-MS/MS) to test for a variety of novel psychoactive substances 
(NPS), including synthetic cathinones. Of the 120 samples that tested positive for NPS, 10% 
tested positive for synthetic cathinones (11 samples for mephedrone, 1 sample for methylone). A 
later study also found high levels of mephedrone in suspected drug users. In France, Martin et al. 
(2012) found that nearly 20% of hair samples collected from those suspected of narcotic abuse 
(13 out of 67) tested positive for mephedrone (Martin et al. 2012). While it is unclear whether 
individuals in either of these studies were aware of synthetic cathinone use, these methods 
confirm the utility of analyzing hair to assess synthetic cathinone use in suspected users. 
In 2015, Palamar and colleagues surveyed and analyzed hair samples from 48 EDM attendees in 
NYC reporting lifetime ecstasy/MDMA/Molly use (Palamar et al. 2016c). Almost half (48%) of 
hair samples contained butylone and 10% contained methylone. However, of those who reported 
no lifetime use of synthetic cathinones or unknown pills or powders, 41% tested positive for a 
synthetic cathinone or other NPS. Specifically, of those denying use of any synthetic cathinones 
listed on the survey, 38% tested positive for butylone, 9% for methylone, and 3% for the highly 
potent compound α-PVP (“Flakka”). This study also found that racial/ethnic minorities were 
more likely to test positive for synthetic cathinones after denying lifetime use. The strongest 
predictor of testing positive for synthetic cathinones was frequent nightclub/festival attendance. 
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In 2016, a similar study was conducted with a focus on 90 past-year ecstasy users in the 
NYC EDM scene (Palamar et al. 2017c). While over a quarter (28%) of attendees tested positive 
for synthetic cathinones, 68% of those testing positive denied past-year use. Butylone (14%), 
ethylone (11%), and pentylone (10%) were the most commonly detected synthetic cathinones - 
strikingly, all participants denied use of these compounds. Methylone was detected in 3% of hair 
samples, but two of these three participants reported known use of this substance. Unknown α-
PVP use was also detected in 2% of samples. These studies demonstrate that many ecstasy-using 
nightclub/festival attendees are unintentionally administering synthetic cathinones, and that drug 
checking may be beneficial for those unwilling or unable to abstain.  
Synthetic cathinone use at EDM parties has also led to clusters of hospitalizations. In 
particular, there were at least 22 drug-related hospitalizations at the 2013 Electric Zoo EDM 
festival in NYC (Ridpath et al. 2014). Of the 22 reported hospitalizations, 9 (41%) were 
classified as severe, and there were two deaths. Of the 22 patients, 17 were administered 
toxicological tests, among whom 55% had used “synthetic club drugs.” Four of the 17 tested 
positive for methylone alone, 3 for methylone and MDMA, 2 for methylone and other illegal 
drugs other than MDMA, and 2 for MDMA alone. One decedent tested positive for MDMA, 
while the other tested positive for both MDMA and methylone. It is unclear whether the second 
decedent or any of the other patients who tested positive for methylone were fully aware of their 
drug/formulation intake. 
Various drug-testing services throughout Europe have also detected a range of synthetic 
cathinones in drugs sold as ecstasy. For example, despite the increasing purity of ecstasy tested 
from 2008-2013 (Brunt et al. 2017), a range of synthetic cathinones including 4‐ MEC, 
mephedrone, methylone, and ethylone were detected in submitted substances. The Drug 
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Information and Monitoring System in the Netherlands in particular detected mephedrone sold as 
ecstasy in a large portion of samples throughout 2009 (Brunt et al. 2011b). A Spanish drug-
testing study also examined drug submissions from 2010-2012 and detected 22 different 
synthetic cathinone compounds (primarily methylone, mephedrone, 4‐ MEC, and MDPV) in 
drugs to be sold as ecstasy or ketamine (Caudevilla-Gálligo et al. 2013). 
It should be noted that while advanced laboratory methods are now able to detect the 
presence of many synthetic cathinones, a major limitation to research is that standard drug tests 
(e.g., urine dip sticks) cannot detect the presence of several dangerous substances. Without a 
simple form of testing, it is difficult for both researchers and medical professionals (e.g., ED 
staff) to test body fluids and determine potential exposure to these compounds. Therefore, 
underestimation of use may continue. However, some harm reduction organizations such as 
DanceSafe sell drug testing reagents which provide users a color-change metric of purity. 
Reagent tests are not the most reliable form of testing, but they can improve ability to detect drug 
adulteration. On-site (e.g., at dance festivals) or off-site testing (e.g., at analytical facilities) can 
help track what drugs people are really using (Butterfield et al. 2016), and this could identify 
specific synthetic cathinones and help detect trends in exposure. Most importantly, drug testing 
is an opportunity for users to discard the drug they plan to use, and results can inform future use 
or decisions to purchase from specific individuals (Butterfield et al. 2016). 
There is a clear need for better testing options and education for clinicians who treat 
suspected synthetic cathinone overdose. ED clinicians must rely heavily on self-reports to 
determine the cause of a drug overdose, in part because urine toxicology tests can take days to 
complete. Vazirian et al. (2015) surveyed ED clinicians and found that 77% do not explicitly ask 
if a patient has taken synthetic cathinones, and 98% were unaware of bath salt urine toxicology 
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tests. While 60% did report having encountered a patient who admitted to bath salts use, these 
patients presented with symptoms that could have easily been misattributed to more common 
drugs of abuse. These symptoms include agitation (81%), aggression or violence (65%), or 
hallucinations (46%) – all common effects of the widely used drugs that synthetic cathinones 
may be intended to mimic. 
Unintentional Synthetic Cathinone Use, Combinatorial Effects, and Underlying 
Neurobiology. 
Unintentional synthetic cathinone use greatly increases the risk of overdose and death. 
The two most common causes of death from synthetic cathinone use are overdose and fatal self-
harm (___citation below____). Our speculation is that overdoses occur because of a fundamental 
misunderstanding of the mechanisms and potencies of the synthetic cathinone(s) being used.  
Self-harm associated with synthetic cathinone use may result from serious psychological effects 
of intoxication such as loss of impulse control, increased risk-taking/sensation-seeking, 
hallucinations, and paranoia (_______). Moreover, chronic use can lead to persistent 
neurochemical alterations that underlie extreme depression, thereby triggering self-harm (Banks 
et al. 2014; Barrio et al. 2016).  
In general, the effects of synthetic cathinones are attributed to the neurotransmitters that 
most illicit drugs act upon including dopamine (DA), noradrenaline (NA) and serotonin (5-HT). 
Drugs such as cocaine function as DA and NA transporter (reuptake) blockers leading to net 
elevations in synaptic neurotransmitter levels. Compared to cocaine, MDPV increases synaptic 
NA with approximately 10-fold- and synaptic DA with approximately 50-fold-greater potency 
(Baumann et al. 2012). Therefore, if one consumes MDPV under the impression that it is 
cocaine, the resulting intoxication would be manifold greater than intended. Excitotoxic levels of 
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DA and NA produce hyperthermia and increased heart rate that can lead to multiorgan failure 
and death (Walter and Carretto 2015).  
Drugs such as MDMA, amphetamine, and methamphetamine act as DA, 5-HT, and NA 
transporter substrates, meaning the drug enters the cell and disrupts vesicular storage and 
transmitter release dynamics (e.g., Baumann et al. 2013). Transporter substrates produce 
persistent depletion of neurotransmitters and loss of functional transporters (Baumann et al. 
2007, 2013; Gygi et al. 1997; German et al. 2014). Indeed depression and suicide are particularly 
common in heavy users of both MDMA and the mechanistically similar synthetic cathinone, 
mephedrone (Cohen 1996; Marinetti and Antonides 2013; Elliott and Evans 2014). 
Death from unintentional synthetic cathinone overdose is typified by one of the first 
reported cases following unintentional “bath salts” consumption. Warrick et al. (2012) describe a 
24-year-old female who died after consuming two pills of what turned out to be high doses of 
methylone and butylone rather than the “ecstasy” she believed she was taking. The patient was 
found unconscious at a concert and was febrile, tachypnic, and hypertensive. An ED exam 
revealed that she was diaphoretic, tremulous, hyperflexic, and had sustained clonus. Despite 
maximal supportive care, optimal ventilation, and improvements in hemodynamics and 
coagulopathy, within 48 hours of admission the patient developed acute respiratory distress 
syndrome, renal failure, hypoxemia, lactic acidosis and ultimately expired. Urinalysis and 
GC/MS testing of pills found on her person similar to the two ingested revealed the sole presence 
of methylone and butylone, with no traces of MDMA that the “ecstasy” was sold as. While 
methylone and butylone are 2-6x less potent than MDMA in terms of DA and 5-HT transporter 
substrate and blocking properties, the excessive quantity of each compound within each pill are 
the likely reason the patient expired. Ecstasy tablets typically contain 30-150 mg of MDMA, and 
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while methylone and butylone are up to 10x less effective at reducing 5-HT and NA, the three 
drugs are similarly effective at increasing DA which may explain why the three drugs are 
consumed recreationally at similar doses (e.g., Hall and Henry 2006; López-Arnau et al. 2012; 
Warrick et al. 2012). In the case described by Warrick et al. (2012), each pill contained 422 mg 
of methylone and 53 mg of butylone - doses that would produce profoundly higher DA levels 
than what is considered pleasurable or safe.  
Unintentional synthetic cathinone use can occur in polydrug users, and a small number of 
preclinical studies have begun to elucidate the neurotoxic and behavioral effects of drug 
combinations. Table 1 lists effects observed in animal subjects following exposure to drug 
combinations that include a synthetic cathinone. Notably, enhancement of neurotoxicity is 
observed with drugs that have overlapping substrate properties (e.g., mephedrone elevates 
MDMA-induced DA neurotoxicity; Angoa-Perez 2013). Some combinations, however, produce 
unexpected protective effects that may be due to the mechanism of one drug minimizing effects 
of a second drug. For example, the DA transporter blocking properties of MDPV may protect 
against the DA releasing properties of methamphetamine (Anneken et al. 2015). In addition, 
many studies fail to account for potential contributions of temperature when examining the 
neurotoxic effects of synthetic cathinone use (alone or in combination with a second drug). For 
example, mephedrone potentiates the neurotoxic effects of MDMA under group- but not single-
housing conditions (Hadlock et al. 2011) which likely reflects the inherent risk of consuming 
these combinations in crowded environments (e.g. EDM clubs). The neurotoxicity observed by 
Hadlock et al. (2011) was persistent yet limited to cells producing 5-HT. In humans, 5-HT 
depletion has been associated with the negative mood, irritability, and suicidal thoughts 
experienced in the days after MDMA or mephedrone use (Cohen 1996; Freeman et al. 2012). 
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More research will be needed to reach a clearer understanding of how synthetic cathinones 
impact the neurochemical and behavioral effects experienced from other drugs when provided, 
knowingly or unbeknownst to the consumer, in polydrug formulations. 
Synthetic cathinone users are at additional risk of experiencing psychosis. There are 
several reported cases of years-long, intermittent mephedrone users entering drug rehabilitation 
for delusional thoughts and auditory and visual hallucinations (Barrio 2016). Psychosis can occur 
in patients with no medical or family history of mental illness demonstrating the profound impact 
of long-term drug use that may have been consumed unknowingly. MDPV can produce delirium 
- a state characterized by bizarre behavior, paranoia, and hallucinations. For example, Penders 
and Gestring (2011) describe 3 cases of individuals experiencing delusions of persecution and 
harassment from nonexistent sources: one man hallucinated his estranged wife tapping on his 
window, a young housewife was filmed describing home invaders in an unoccupied room, and a 
middle-aged man hallucinated burglars shooting him with laser beams. Moreover, the memory 
disturbances common in MDPV-induced delirium greatly increase the risk of overdose death 
because patients frequently have no recollection of the amount, frequency, or route of 
administration. This is especially dangerous in the case of unintentional use of MDPV, of a drug 
that is over ten times more potent than the more common substance it may have been intended to 
mimic (e.g. cocaine). These cases demonstrate the great risk involved in consuming a substance 
that may be far more potent than one conceives.  
Finally, unintentional synthetic cathinone use carries with it significant risk of death from 
self-harm. Self-harm has been cited as the second most common cause of death in synthetic 
cathinone users (Schifano et al. 2012; Marinetti and Antonides 2013). A 3-year review of novel 
psychoactive substances in casework (Elliott and Evans 2014) found that in deaths following 
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synthetic cathinone use, 41% were hangings or other mechanical suicide (i.e., fatal self-harm), 
which was the highest proportion compared to other classes of drugs. While hangings are the 
most common form of fatal self-harm, drownings, gunshots wounds, repeated self-lacerations, 
and jumping from bridges have all been reported (Schifano et al. 2012; Marinetti and Antonides 
2013).  
Self-harm related to synthetic cathinone use is attributed to impulsivity, paranoia, and 
violent behavior in response to vivid hallucinations or delusional thoughts (Penders 2012; 
Penders and Gestring 2011). In a case of fatal self-harm associated with synthetic cathinone use, 
a 21-year old with no history of depression committed suicide 5 days after ingesting an unknown 
powder later determined to be MDPV (PBS News, 2018). The decedent experienced days of 
insomnia and a frightening hallucination of 25 police cars outside his kitchen. Upon being told 
the police cars did not exist, the patient slit his throat in front of his parents. The self-inflicted 
laceration was non-fatal and was successfully stitched closed at a hospital. However, 4 hours 
after returning home from the hospital, and 5 days after initial drug-taking, the decedent 
committed suicide with a rifle. This case exemplifies how MDPV use can promote self-harm and 
suicide, possibly as a consequence of withdrawal-associated affective distress. It is likely the 
decedent was experiencing excitotoxic levels of DA during the psychotic episode. Synthetic 
cathinone-induced DA excitotoxicity can take days to normalize (Den Hollander et al. 2013; 
Martínez-Clemente et al. 2014), during which depression and suicidal thoughts may emerge. 
Indeed, the term “suicide tuesday” emerged to describe the depressive withdrawal state 
experienced days following initial drug-taking (Psychedelics.com 2018).  It is possible that 
antipsychotic treatment may have prevented death of the patient, as antipsychotic drugs working 
as DA modulators synthetic cathinone-induced psychosis (Banks et al. 2014; Barrio et al. 2016).  
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ED clinicians and potential drug users can reduce the risk of overdose and death from 
unintentional synthetic cathinone use. Clinicians should be aware of the constellation of 
symptoms typical of synthetic cathinone overdose: agitation, sustained hyperthermia, muscle 
rigidity, and psychosis. The typical course of treatment involves aggressive cooling, hydration, 
and antipsychotic medication administration. Additionally, drug users who reject abstinence can 
make use of pill-testing services that can reliably detect the presence of ‘unknown substances’ in 
drugs such as cocaine and ecstasy (Saleemi et al. 2017). Drug users and clinicians should also 
note the potential for self-harm and suicide in patients during intoxication and during 
withdrawal. Future studies examining the toxicity associated with synthetic cathinone drug 
combinations are also needed to better address the emerging phenomenon of unintentional 
synthetic cathinone use.  
Concluding Remarks. 
Adulteration of illegal drugs with synthetic cathinones is an untenable yet largely 
unrecognized public health concern, the magnitude of which we are only beginning to appreciate 
through empirical observation. Traditional approaches used to assess the effects of drugs on 
public health and safety (e.g., surveys, urinalysis) are likely underestimating synthetic cathinone 
use, especially in high-risk populations. Moreover, synthetic cathinone abuse carries with it risks 
unique to this class of drugs such as overdose, self-harm, and suicide. It is clear that synthetic 
cathinones mimicking relatively popular illegal drugs such as cocaine (e.g., MDPV) and MDMA 
(e.g., methylone and mephedrone) produce similar euphorigenic subjective effects, though 
typically at fractions of the dose.  
We believe the burden of addressing this public health problem is complicated and shared 
by many. In effort to specifically reduce accidental overdose, we advocate the development and 
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commercial sale of purity detectors (e.g. pill-testing products and services) that can be employed 
by users. We advocate the dissemination of accurate, empirically-derived information on the 
effects of synthetic cathinones so users and medical professionals including ED personnel can 
recognize when an individual - knowingly or not - has consumed a synthetic cathinone. 
Moreover, ED personnel should be aware of the availability of synthetic cathinone drug-testing 
products and services. In the future, collaborative work between field observers and basic 
scientists will (i) clarify the extent to which synthetic cathinones impact the subjective and 
physiological effects associated with other drug use, (ii) determine how situational factors such 
as environment influence the effects of synthetic cathinones taken with other drugs, and (iii) aide 
in the development of medical intervention strategies associated with the unique risks of drug use 
complicated by synthetic cathinone adulteration. 
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Tables. 
Table 1. Neurotoxic and Behavioral Effects of Synthetic Cathinones in Combination More 
Commonly Used Illegal Drugs. Synthetic cathinones can potentiate, nullify, or protect against 
the neurotoxic and behavioral effects of more commonly used drugs (second drug).  
Synthetic 
cathinone 
Common Illegal 
Drug 
Effects (neurotoxic or 
behavioral) 
Reference (format) 
Mephedrone MDMA Potentiates MDMA-induced 
DA and 5-HT neurotoxicity in 
group-housed animals 
Hadlock et al. 2011 
MDPV Methamphetamine Reduced methamphetamine-
induced DA neurotoxicity 
Anneken 2015 
Methylone 
Methylone MDMA Reduced MDMA-elicited 
astrogliosis and neurotoxicity 
markers 
Miner 2017 
Mephedrone MDMA No effect on 5-HT 
neurotoxicity 
Angoa-Perez 2014 
 
Methamphetamine  
Mephedrone MDMA Reduced depression, improved 
memory consolidation 
Budzynska 2017 
Mephedrone Methamphetamine Enhanced DA neurotoxicity Angoa-Perez 2013 
Amphetamine  
MDMA 
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